Shanghai Techwell Biopharmaceutical Co., Ltd.

Mili Youhe Home Technology (shanghai) Co, Ltd

Shanghai Techwell Biopharmaceuticals Co., Ltd.

Xiaoming Ji

Shidong Liu

Zhijun Tang

Zhaoli Zhang

Bingming He

Zhonghao Zhuo

Jun Zhu

Xiusheng Wang

Xiaoliang Gao

Yi Chen

Ying Xue

Yunhai Hong

Jing Xu

Jun Yang

Lixin Sha

Yubin Liu

Yan Li

Xiao Xun Zhang

Yunman Zheng

Tianhui Xu

Guangjun Jiao

Chunxia Wang

Jing Kang

Mingquan Mei

Liangliang Zhou

Yong Yao

Xiao Zhang

Jicheng Hu

Ming Li

Provided is a fitness tool storage case. The fitness tool storage case includes: a first case body, and a second case body movably connected to the first case body. The first case body and the second case body can be in a storage state of being enclosed into a storage chamber and an open state of being stacked; in the storage state, at least one of a plurality of fitness tools is arranged in the storage chamber; and in the open state, at least one of the plurality of fitness tools can be exposed for being fetched by a user. According to the fitness tool storage case provided in the embodiments of the present disclosure, the plurality of fitness tool can be stored/placed. When the fitness tools are not used, an occupied space is reduced, and a user experience is enhanced.

Fitness tool storage case

A fitness tool kit is provided. The fitness tool kit includes a plurality of fitness tools and a storage case. The storage case is configured to store/place the plurality of fitness tools. According to the fitness tool kit provided in the embodiments of the present disclosure, by the arrangement of the storage case, the plurality of fitness tools can be stored/placed. When the fitness tools are not used, an occupied space is reduced, and a user experience is enhanced.

Fitness tool kit

Disclosed in the present invention are an immobilized cycloaliphatic peptide acyltransferase and a preparation method and use thereof. The cycloaliphatic peptide acyltransferase is immobilized on a carrier; the cycloaliphatic peptide acyltransferase is derived from natural or artificial mutants or variants thereof, or can be obtained by introducing a foreign cyclic acyltransferase gene and transforming thereafter; the material of the carrier is selected from an inorganic carrier or a polypropylene resin carrier. Also disclosed in the present invention are the preparation method for the immobilized cycloaliphatic peptide acyltransferase and uses thereof.

Immobilized cycloaliphatic peptide acyltransferase and preparation method and uses thereof

Provided in the invention is a solvate of a cyclic peptide compound, represented by formula I is the structural formula of the cyclic peptide compound, and, also disclosed are a preparation method for same and uses thereof. 

Solvate of cyclic peptide compound, preparation method for same, and uses thereof

Disclosed is a novel polymorph of a cyclic peptide compound, the structure whereof is represented by formula I; also disclosed are a preparation method for same and uses thereof. 

Crystal of cyclic peptide compound, preparation method for same and uses thereof

Disclosed is a crystalline powder of a cyclic peptide compound, represented by formula I is the structure of same, and, also disclosed are a preparation method for same and uses thereof. 

Crystalline powder of cyclic peptide compound, preparation method for same, and uses thereof

A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal. 

High-purity cyclopeptide crystal as well as preparation method and use thereof

Provided is a method for preparing a compound represented by Formula I or a salt thereof, whereinF-11899 (FERM BP2635) and/or a mutant strain thereof is cultured in a medium containing amino acid or a salt thereof, an insoluble organic source, and a sugar alcohol, to produce the compound of Formula I or a salt thereof. 

Method for preparing cyclic lipopeptide compound

Disclosed are a high purity of caspofungin or salts thereof, and a preparation method thereof, and use thereof. Disclosed are a caspofungin or salts thereof with low solvent residue and hyposaline, and a preparation process comprising: dissolving a crude product of caspofungin or salts thereof into a system of water and acetic acid, then mixing with a first organic solvent ethyl alcohol, subsequently mixing with a second organic solvent ethyl acetate, then being subject to filtration and drying together with water, to obtain caspofungin or salts thereof with high stability, low solvent residue and hyposaline.

Caspofungin or salts thereof with high purity, as well as preparation method and use thereof

Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9&#xb1;0.2&#xb0;, 6.5&#xb1;0.2&#xb0;, 12.6&#xb1;0.2&#xb0;, 13.1&#xb1;0.2&#xb0; and 20.6&#xb1;0.2&#xb0;. 

Crystal form of prostaglandin analogue, and preparation method and use thereof

Provided are a crystal form A of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form A has characteristic peaks at the following diffraction angles: 2.9&#xb1;0.2&#xb0;, 13.6&#xb1;0.2&#xb0;, 17.3&#xb1;0.2&#xb0; and 18.6&#xb1;0.2&#xb0;. 

A purification method of the compound represented by formula 1 is provided, which includes the following steps: (1) loading crude compound 1 on macroporous adsorbent resin, (2) washing the macroporous adsorbent resin with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water, (3) eluting with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water. The purified compound represented by formula 1 is obtained. 

Purification method of azacyclohexapeptide or its salt

Disclosed is a low impurity content caspofungin pharmaceutical composition and a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition comprises the compound of formula I and/or a pharmaceutically acceptable salt thereof, in combination with a saccharide protective agent(s) and an amino acid(s). The caspofungin pharmaceutical composition is prepared by dissolving the saccharide protective agent and the amino acid into water or a suitable buffer solution; adding the caspofungin compound and dissolving it; filtering the solution and lyophilizing.

Low impurity content caspofungin preparation, method for preparing same, and use thereof

The method of the preparation of micafungin sodium comprises the step of mixing the weak base and the aqueous solution containing micafungin acid (the structure is illustrated by formula I) or the mixed aqueous solution containing the compound of formula I and organic solvent in order to obtain the sodium salt of micafungin (the structure is illustrated by formula II). 

Growing community of inventors

Shanghai, China

Xiaoming Ji